La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California. La Jolla Pharmaceutical aimed to eliminate diseases. The development-stage firm was working with Toleragens, proprietary therapies that block the abnormal antibody production associated with certain autoimmune disorders without suppressing the entire immune system. Its lead drug candidate was Riquent, a treatment for renal disease associated with lupus. The drug would have been one of the few new drugs for lupus, and was being considered as a treatment for other autoimmune disorders. However, the company ceased most of its operations after trials of Riquent failed in 2009. Adamis Pharmaceuticals has announced it intends to acquire La Jolla Pharmaceuticals.
Contact Details
Office Address
La Jolla Pharmaceutical Company
4365 Executive Drive, Suite 300
San Diego, CA, USA 92121-2125
Phone: (858) 452-6600
Fax: (858) 626-2851
Executives
Chairman
Craig R. Smith
President, CEO, Assistant Secretary, and Director
Deirdre Y. Gillespie